Jay Olson
Stock Analyst at Oppenheimer
(3.61)
# 806
Out of 4,876 analysts
246
Total ratings
41.24%
Success rate
8.24%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 → $22 | $22.07 | -0.32% | 15 | Jun 26, 2025 | |
| PRAX Praxis Precision Medicines | Assumes: Outperform | $97 | $43.76 | +121.66% | 1 | Jun 2, 2025 | |
| PRTA Prothena Corporation | Downgrades: Perform | n/a | $6.23 | - | 14 | May 27, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $65 | $24.77 | +162.47% | 1 | May 21, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 → $65 | $5.79 | +1,023.60% | 5 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $15 → $13 | $2.22 | +485.59% | 3 | May 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $75 | $37.70 | +98.94% | 9 | May 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $25 → $21 | $3.65 | +475.34% | 2 | May 7, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Outperform | $90 | $27.65 | +225.50% | 6 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $50 → $42 | $14.43 | +191.06% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $43.80 | -24.66% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $9.68 | +313.22% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $1.60 | +1,150.00% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $8.02 | +274.06% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $3.86 | +418.13% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $127.35 | +100.24% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $9 → $8 | $9.28 | -13.75% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $69.61 | +17.80% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $303.21 | +15.43% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $3.45 | +189.86% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $27.06 | +409.98% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.01 | +298.01% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $7.35 | +553.06% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $280.61 | +35.42% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $127.08 | +72.33% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.25 | +433.33% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $2.95 | +511.21% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.81 | +1,137.47% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $46.90 | +102.56% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.59 | +445.26% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $39.74 | +88.73% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.32 | +2,692.43% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $9.89 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $1.01 | +4,830.48% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $7.69 | +173.08% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.66 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $19.50 | +330.77% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.13 | - | 3 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19 → $22
Current: $22.07
Upside: -0.32%
Praxis Precision Medicines
Jun 2, 2025
Assumes: Outperform
Price Target: $97
Current: $43.76
Upside: +121.66%
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $6.23
Upside: -
Tvardi Therapeutics
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $24.77
Upside: +162.47%
Jasper Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $5.79
Upside: +1,023.60%
Inovio Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $2.22
Upside: +485.59%
Revolution Medicines
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $37.70
Upside: +98.94%
Immuneering
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $3.65
Upside: +475.34%
Nektar Therapeutics
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $27.65
Upside: +225.50%
Denali Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $14.43
Upside: +191.06%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $43.80
Upside: -24.66%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $9.68
Upside: +313.22%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.60
Upside: +1,150.00%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $8.02
Upside: +274.06%
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $3.86
Upside: +418.13%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $127.35
Upside: +100.24%
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $9.28
Upside: -13.75%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $69.61
Upside: +17.80%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $303.21
Upside: +15.43%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $3.45
Upside: +189.86%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $27.06
Upside: +409.98%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $2.01
Upside: +298.01%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $7.35
Upside: +553.06%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $280.61
Upside: +35.42%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $127.08
Upside: +72.33%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.25
Upside: +433.33%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $2.95
Upside: +511.21%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.81
Upside: +1,137.47%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $46.90
Upside: +102.56%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $4.59
Upside: +445.26%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $39.74
Upside: +88.73%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.32
Upside: +2,692.43%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $9.89
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $1.01
Upside: +4,830.48%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $7.69
Upside: +173.08%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.66
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $19.50
Upside: +330.77%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.13
Upside: -